5 results
The primary objective of this study is to assess the efficacy of pridopidine 67.5 to 112.5 mg twice daily (bid) on motor impairment in patients with HD after 26 weeks of treatment using the Unified Huntington*s Disease Rating Scale (UHDRS) Total…
To investigate the effect of a sunscreen, a topical antioxidant and a topical corticosteroid on erythema, infiltrating neutrophils and oxidative stress following exposure of the skin to SSR.
Primary Objective: The primary objective of this study is to evaluate safety and tolerability of pridopidine in patients with HD.Secondary Objectives: The secondary objectives of the study are to assess the effects of long-term, open-label dosing…
The purpose of this Phase 3 study is to further evaluate the effect of pridopidine 45*mg BID on functional capacity, as well as motor and behavioral features of HD in early-stage participants (TFC*713).
Objectives: Main objective: A personalized intervention of patients* stress and anxiety based on the combined use of standard measures (e.g. questionnaires) and advanced tools (smart watch sensors, mHealth app and VR) through a radical Artificial…